Facebook
Twitter
LinkedIn
Forward
The Surgical Management of BPH and Updates from the AUA Clinical Guidelines Webcast (2024)
As a direct result of the evolving technologies and procedures related to the surgical management of BPH, urologists must continue increasing their knowledge and skills of the various treatment options available.
Designed for urologists and other healthcare professionals involved in the treatment of BPH, this 2-hour, interactive discussion- based course, will provide a practical application on how the newly updated 2023 Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Clinical Guideline applies in day-to day practice with a patient centered focus. Led by renowned experts in the field, the course will also discuss the evidence base for several surgical techniques including temporary implantable nitinol devices, prostatic artery embolization, high-pressure saline hydro dissection and laser enucleation techniques.
Presented in English, the activity is of value to the global urologic community.
Acknowledgements:
This educational series is supported by an independent educational grant from Olympus Corporation of the Americas.
Target Audience
- Urologists
- Advanced Practice Providers (Nurse Practitioners, Physician Assistants, Nurse Navigators)
Learning Objectives
After participating in this educational series, participants will be able to:
- Describe the role of the AUA Clinical Guideline on the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia.
- Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectation for each of them.
- Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics.
- Differentiate between each of the new technologies for treating BPH/LUTS based on both their mode-of-action and the quality of their supporting evidence.
Education Council Disclosures
Education Council Disclosures_2024_01_25.pdf
COI Review Work Group Disclosures
COI Review Work Group Disclosures.pdf
Faculty Disclosures
Surgical Management of BPH Webinar Series- Fnal Disclosures.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
Method of Participation: Learners will participate in this online educational activity by viewing the webcast, answering multiple choice questions, examining patient tools and resources and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Release Date: July, 2024
Expiration Date: July, 2025
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification relevant financial relationships that result in of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation